(Q35186888)

7 August 2017

1 reference

title

Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia (English)

1 reference

7 August 2017

1 reference

Morgan MA

1

1 reference

7 August 2017

Ganser A

series ordinal

2

1 reference

7 August 2017

Reuter CW

series ordinal

3

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

17

1 reference

7 August 2017

issue

8

1 reference

7 August 2017

page(s)

1482-1498

1 reference

The Ras branch of small GTPases: Ras family members don't fall far from the tree

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Reversible palmitoylation of signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Signal transduction from multiple Ras effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Evidence for a Ras/Ral signaling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

21 January 2018

Phosphoinositide kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Synergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Suppression of apoptosis: role in cell growth and neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Mutations of K-ras oncogene in human adrenal tumours in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Decreased GTPase activity of K-ras mutants deriving from human functional adrenocortical tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

G protein mechanisms: insights from structural analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The molecular pathophysiology of myeloid leukaemias: Ras revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

RAS and leukemia: from basic mechanisms to gene-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Genetic heterogeneity in acute myeloid leukemia: maximizing information flow from MuLV mutagenesis studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The molecular genetics of Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The biology of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Nf1 and Gmcsf interact in myeloid leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

BAY 43-9006: early clinical data in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Protein prenylation: molecular mechanisms and functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Recent advances in the study of prenylated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Structure, mechanism and function of prenyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Therapeutic intervention and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Ras biochemistry and farnesyl transferase inhibitors: a literature survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: cleavage of the common alpha subunit during apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Rho GTPases and the actin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Rho GTPases in cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Rho GTPases and their effector proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Rho family proteins: coordinating cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Anions modulate the potency of geranylgeranyl-protein transferase I inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Novel lipid-regulating drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Cell cycle-specific effects of lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Lovastatin induces a pronounced differentiation response in acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Farnesyl transferase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Analysis of RAS oncogene mutations in human lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Ras oncogene mutation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

21 January 2018

Role of FLT3 in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Transforming properties of the Huntingtin interacting protein 1/ platelet-derived growth factor beta receptor fusion protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Identification of four new translocations involving FGFR1 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Chromosomal translocations joining LCK and TCRB loci in human T cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Rab geranylgeranyl transferase catalyzes the geranylgeranylation of adjacent cysteines in the small GTPases Rab1A, Rab3A, and Rab5A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

The gamma subunit of transducin is farnesylated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Farnesylcysteine, a constituent of the alpha and beta subunits of rabbit skeletal muscle phosphorylase kinase: localization by conversion to S-ethylcysteine and by tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

Farnesyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Effects of deregulated Raf activation on integrin, cytokine-receptor expression and the induction of apoptosis in hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

c-kit point mutation of extracellular domain in patients with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403024

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403024

1 reference

7 August 2017

1 reference